Cyclerion Therapeutics Inc (CYCN) Stock Price, Quote & News

Company Profile

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebi...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8778

Website: www.cyclerion.com

Address:

245 First Street, Riverview II, 18th Floor, Cambridge, United States

spinooch Feb. 24 at 9:32 PM

$CYCN theres a group of folks on this board who are way more in tune than me. What time frame are we looking at? I hate having capital tied up in zero liquidity trades. I have 14k shares now and at this rate it will take a week to sell them.

1 · Reply

StockTwitsGhost Feb. 24 at 6:39 AM

$CYCN Of the three non-dilutive sources, the Tisento 10% stake is the most powerful as it represents equity appreciation, not just milestone fees, functioning essentially as a venture capital return embedded inside a small-cap biotech. Cyclerion’s anti-dilution protections have shielded their ownership through the Series A, but those protections expire once Tisento crosses the $100M cumulative funding threshold, a ceiling a Series B would almost certainly breach. That creates a hard deadline: Cyclerion must execute a secondary sale before or concurrent with the Series B closing, making Q2-3 2026 the optimal and likely only clean exit window, yielding $15M–$25M in non-dilutive liquidity that bridges the company to Phase 2 data readout without a massively dilutive public offering. We are very close.

2 · Reply

StockTwitsGhost Feb. 24 at 6:37 AM

$CYCN @skyrockets_Inc The appearance of “non-dilutive capital from historical portfolio” on slide 17 of Cyclerion’s active February 2026 investor deck, is in my opinion being shown to institutional investors right now, it is not boilerplate language. It’s the board explicitly marketing the Tisento stake, Akebia milestones, and Olinciguat as a funding bridge to limit how much burden falls on the PIPE, making dilution more palatable and PIPE terms more attractive to institutional buyers. This is classic pre-PIPE deck architecture. The deck being live in February 2026 strongly suggests a PIPE close in Q2 2026 (April–May), with the early-March 10-K serving as the de-risking disclosure that unlocks institutional commitments.

0 · Reply

StockTwitsGhost Feb. 23 at 8:58 PM

$CYCN In my opinion a "convergence point“ is near and the timing is likely 1–2 weeks out. The most probable scenario is that the market continues to digest the February 17 FDA news, with the 10-K and associated strategic updates arriving between March 2 and March 15. This week represents the "quiet before the storm" but the storm itself is coming.

2 · Reply

Mr_Pithy Feb. 23 at 5:38 PM

$CYCN Phase 2 trial for CYC-126. Positive Feedback from FDA. $8.00 per share. Good luck 🍀 to all of us.

0 · Reply

ZacksSCR Feb. 23 at 4:54 PM

$CYCN: Positive Feedback from FDA Sets Stage for Phase 2 Trial of CYC-126 in 2H26 https://buff.ly/7eMGE5S

1 · Reply

defman Feb. 23 at 3:11 PM

$CYCN

0 · Reply

StockTwitsGhost Feb. 21 at 8:33 PM

$CYCN This 🐂🧸💩 talks out of both sides of his mouth , first downplaying it as a “5–15% chance” they ever received money from AKBA and saying millions already received are meaningless, then stretching timelines to 1–4 years while still dangling “$BIG.X$.” It’s constant contradiction with no consistent stance.

2 · Reply

skyrockets_Inc Feb. 19 at 9:04 PM

$CYCN All great posts, but this last one is the perfect summary. I was telling a colleague this the other day. Eveyrthing they've been working on that's been taking forever seems to all be culminating at the same time in this first half of 2026. All of them lining up perfectly. Tisento, Olinciguat, Praliciguat, funding for TRD, etc.....highest density catalyst window is a perfect description. Add in the large short prescense trying to hold it down and the perfect storm might be a brewin'

1 · Reply

StockTwitsGhost Feb. 19 at 7:18 PM

$CYCN 🦜 Bottom Line on Timing The 2025 annual 10-K filing, due in approximately two weeks, is not just a routine financial update — it is a convergence point for every single thesis driver simultaneously: updated cash, Tisento stake value, Akebia payment confirmation, going concern status, CYC-126 program investment, and subsequent events disclosures covering everything that has happened in the first weeks of 2026. Combined with the February 17 FDA catalyst already public and a Tisento Series B that could drop at any moment, the next two to four weeks represent the highest-density catalyst window in Cyclerion’s recent history — and the stock at $1.37 is almost certainly being priced by a market that has no idea any of this is coming.

0 · Reply

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Jan 6, 2026, 10:28 AM EST - 7 weeks ago

Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript

Jan 5, 2026, 4:01 PM EST - 7 weeks ago

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

Sep 24, 2025, 12:53 PM EDT - 5 months ago

Cyclerion Therapeutics, Inc. - Pre Recorded Special Call

Sep 23, 2025, 4:01 PM EDT - 5 months ago

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

Dec 17, 2024, 8:08 AM EST - 1 year ago

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Dec 4, 2023, 8:00 AM EST - 2 years ago

Cyclerion Appoints Regina Graul, Ph.D., as President

Nov 30, 2023, 6:16 PM EST - 2 years ago

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

Jul 31, 2023, 7:00 AM EDT - 2 years ago

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

Jun 1, 2023, 4:00 PM EDT - 2 years ago

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 15, 2023, 1:00 PM EDT - 3 years ago

Cyclerion Announces Reverse Stock Split

May 11, 2023, 6:00 PM EDT - 3 years ago

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

May 11, 2023, 6:00 PM EDT - 3 years ago

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Apr 3, 2023, 7:30 AM EDT - 3 years ago

Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

Mar 22, 2023, 4:40 PM EDT - 3 years ago

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

Nov 22, 2022, 7:00 AM EST - 3 years ago

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

Aug 9, 2022, 4:00 PM EDT - 3 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Jul 28, 2022, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Jul 26, 2022, 7:00 AM EDT - 3 years ago

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

Jun 28, 2022, 9:00 AM EDT - 3 years ago

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 22, 2022, 8:30 AM EDT - 3 years ago

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 17, 2022, 11:27 AM EDT - 4 years ago

Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies

Jun 17, 2022, 8:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Jun 10, 2022, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Jun 6, 2022, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

May 4, 2022, 4:01 PM EDT - 4 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Feb 24, 2022, 4:01 PM EST - 4 years ago

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Feb 23, 2022, 8:00 AM EST - 4 years ago

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Jan 26, 2022, 8:00 AM EST - 4 years ago

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Vascular Pathology

Nov 11, 2021, 5:32 PM EST - 4 years ago

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference

Nov 9, 2021, 4:01 PM EST - 4 years ago

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

Oct 26, 2021, 4:29 PM EDT - 4 years ago

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 20, 2021, 4:24 PM EDT - 4 years ago

Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside

Sep 22, 2021, 8:00 AM EDT - 4 years ago

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Aug 23, 2021, 5:00 PM EDT - 4 years ago

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

Jul 29, 2021, 5:00 PM EDT - 4 years ago

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

Jul 22, 2021, 4:30 PM EDT - 4 years ago

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)

Jul 9, 2021, 6:14 AM EDT - 5 years ago

Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers

Jul 8, 2021, 7:22 PM EDT - 5 years ago

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

Jul 8, 2021, 4:30 PM EDT - 5 years ago

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership

Jun 4, 2021, 10:27 AM EDT - 5 years ago

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise

AKBA

Jun 4, 2021, 8:00 AM EDT - 5 years ago

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

Jun 4, 2021, 8:00 AM EDT - 5 years ago

Cyclerion Therapeutics Announces $18 Million Private Placement

May 27, 2021, 4:30 PM EDT - 5 years ago

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

May 25, 2021, 7:00 AM EDT - 5 years ago

Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference

Apr 27, 2021, 12:03 PM EDT - 5 years ago

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

BNGO ALDX SLGL

Apr 27, 2021, 9:00 AM EDT - 5 years ago

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress

spinooch Feb. 24 at 9:32 PM

1 · Reply

StockTwitsGhost Feb. 24 at 6:39 AM

2 · Reply

StockTwitsGhost Feb. 24 at 6:37 AM

0 · Reply

StockTwitsGhost Feb. 23 at 8:58 PM

2 · Reply

Mr_Pithy Feb. 23 at 5:38 PM

$CYCN Phase 2 trial for CYC-126. Positive Feedback from FDA. $8.00 per share. Good luck 🍀 to all of us.

0 · Reply

ZacksSCR Feb. 23 at 4:54 PM

$CYCN: Positive Feedback from FDA Sets Stage for Phase 2 Trial of CYC-126 in 2H26 https://buff.ly/7eMGE5S

1 · Reply

defman Feb. 23 at 3:11 PM

$CYCN

0 · Reply

StockTwitsGhost Feb. 21 at 8:33 PM

2 · Reply

skyrockets_Inc Feb. 19 at 9:04 PM

1 · Reply

StockTwitsGhost Feb. 19 at 7:18 PM

0 · Reply

StockTwitsGhost Feb. 19 at 7:13 PM

$CYCN More from 🦜 Cyclerion (CYCN) at $1.37 per share and a $4.8M total market cap represents one of the most glaring sum-of-parts mispricings in all of small-cap biopharma: the market has become so fixated on the going-concern warning that it has stopped reading entirely, failing to compute that sitting inside this $4.8M shell is a $560 million contingent milestone stack from Akebia alone — 117 times the entire current market cap — plus tiered royalties on praliciguat ranging up to 20% of sales in a multi-billion dollar kidney disease market that the market is pricing at exactly zero; a 10% equity stake in Tisento Therapeutics carried at $5.35M on the books — already exceeding the entire CYCN market cap — but which is almost certainly worth $20-70M+ once Tisento announces its overdue Series B at a valuation reflecting its FDA Fast Track designation, fully enrolled global Phase 2b PRIZM study in MELAS, and top-tier VC backers including Invus, Sanofi Ventures, and Venrock,

2 · Reply

StockTwitsGhost Feb. 19 at 7:02 PM

$CYCN Larry🦜 Part 2 The positive FDA feedback just two days ago was a deliberate setup. Cyclerion’s February 17, 2026 announcement of positive pre-IND FDA written feedback on CYC-126 and the formation of its five-member Clinical Advisory Board is textbook pre-financing announcement activity. Companies do not spend money assembling star-studded advisory boards and announcing FDA feedback unless they are simultaneously pitching investors. This announcement was almost certainly timed to anchor a financing roadshow narrative — giving Ivanov or whoever the banker is a concrete, credible catalyst to show institutional investors.

0 · Reply

StockTwitsGhost Feb. 19 at 7:01 PM

$CYCN Larry🦜 A capital raise is not “soon” — it is overdue and likely already in active negotiation right now. The Tisento stake is carried at $5.35 million. The auditor identified the assessment of impairment indicators for Cyclerion’s $5.350 million investment in Tisento Therapeutics Holdings Inc. as a critical audit matter — but notably, no impairment was recognized as of December 31, 2024. This is crucial: Cyclerion’s own carrying value of Tisento is $5.35M — essentially equal to the entire current market cap of CYCN. The market is pricing Cyclerion’s own operating pipeline at close to zero, and Tisento at book value only. If the Tisento Series B reprices that stake significantly higher, it immediately changes the math on what CYCN is worth.

0 · Reply

StockTwitsGhost Feb. 19 at 6:53 PM

$CYCN I’ve never seen Larry🦜 this excited. LarryB wont S-Up. Cyclerion (CYCN) is a $4.76M market cap public company — but it also owns 10% of Tisento Therapeutics, a well-funded private rare disease company with FDA Fast Track, a fully enrolled global Phase 2b study, top-tier VC backers, and a Series B that is almost certainly imminent. That Tisento stake alone could be worth multiples of CYCN’s entire market cap. Simultaneously, Cyclerion just received positive FDA feedback on its own CYC-126 TRD program. Vlad Ivanov at AmerX — a boutique healthcare banker with a career built on exactly these types of micro-cap biotech financings — is actively engaging with Cyclerion, almost certainly positioning to serve as placement agent for a capital raise that would be marketed to investors around both the Tisento value catalyst and the FDA-endorsed TRD pipeline. The Tisento Series B, when it lands, is the match that lights the fire.

1 · Reply

StockTwitsGhost Feb. 19 at 6:41 PM

$CYCN Larry🦜 Prefers Killington over Stratton. Lucid Capital Markets (“Lucid”), doing business as Americas Executions (“AmerX”), is a member of the New York Stock Exchange as well as an SEC and FINRA-registered broker-dealer. As one of the largest firms on the NYSE trading floor, AmerX and its team have decades of cumulative experience in financial markets, managing an array of products and offering a bespoke suite of services. As a full-service Broker Dealer, AmerX provides tailored Securities Lending services, custody and clearing as well as Investment Banking solutions to its clients.

0 · Reply

skyrockets_Inc Feb. 19 at 4:05 PM

$CYCN Good news is shorts are still paying 130% borrow fees. The slow squeeze is continuing. Slow trickle up until financing news then 💥

0 · Reply

StockTwitsGhost Feb. 18 at 11:40 PM

$CYCN Great find. Based on a quick review of Vlad Ivanov Linkedin, he is the ”Managing Director, Co-Head of Healthcare Investment Banking at Lucid Capital Markets” and among other thing's specializes in PIPE’s. Ski Stratton is a small community ⛷️❄️

1 · Reply

skyrockets_Inc Feb. 18 at 11:06 PM

$CYCN Something seems different this time. I feel like something big coming soon. I can feel it in my loins. 1.41 AH @Bullbear1010101 !

2 · Reply

StockTwitsGhost Feb. 18 at 9:05 PM

$CYCN Yawn. So boring. I really want a 10x day. Is that too much to ask for?

1 · Reply

Thrand11 Feb. 18 at 7:24 PM

$CYCN

0 · Reply

EZYME22 Feb. 18 at 6:41 PM

$CYCN Lucid capital markets served as Sensei advisor. Guess who liked Cyclerions recent PR/linkedin post?

1 · Reply

EZYME22 Feb. 18 at 6:32 PM

$CYCN

0 · Reply

Market Cap	5.18M
Revenue (ttm)	2.00M
Net Income (ttm)	-3.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-153.00%
Debt to Equity Ratio	0.00

Volume	25,500
Avg Vol	1,832,108
Day's Range	N/A - N/A
Shares Out	3.93M
Stochastic %K	77%
Beta	0.98
Analysts	Strong Buy
Price Target	$8.00